Condition: Solid Tumors · Hematologic Malignancies · Sponsor: Incyte Corporation
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| City of Hope Medical Center | Duarte, California, United States | Recruiting |
| University of California San Diego Medical Center, Moores Cancer Center | La Jolla, California, United States | Not Yet Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Not Yet Recruiting |
| The University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Not Yet Recruiting |
| Scri Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| Vanderbilt Medical Center | Nashville, Tennessee, United States | Not Yet Recruiting |
| Md Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Macquarie University Hospital | Sydney, New South Wales, Australia | Recruiting |
| Princess Alexandra Hospital Australia | Woolloongabba, Queensland, Australia | Recruiting |
| Cancer Research Sa | Adelaide, South Australia, Australia | Recruiting |
| Peter Maccallum Cancer Centre-Royal Melbourne Hospital | Melbourne, Victoria, Australia | Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07195916